- Alzamend Neuro Inc ALZN contracted Altasciences to conduct a six-month Phase 1 comparative bioavailability study for AL001 for dementia related to Alzheimer's disease in September 2021.
- AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment.
- The Phase 1 study will investigate the pharmacokinetics of lithium following a single dose of AL001 compared to a typical single dose of a marketed 300 mg immediate-release lithium carbonate capsule in healthy subjects.
- The lithium and salicylate components of AL001 will be given within the amounts already approved for use in patients.
- Related: Alzamend Neuro's Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models.
- Price Action: ALZN shares are down 4.77% at $3.33 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
